Dataset related to article "Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide "
Creators
-
Jacopo Mariotti1
- Anna Maria Raiola2
- Andrea Evangelista3
- Samia Harbi4
- Francesca Patriarca5
- Michele Angelo Carella6
- Massimo Martino7
- Antonio Risitano8
- Alessandro Busca9
- Luisa Giaccone10
- Lucia Brunello9
- Emanuela Merla11
- Lucia Savino11
- Barbara Loteta7
- Giuseppe Console7
- Renato Fanin5
- Alessandra Sperotto5
- Luana Marano8
- Serena Marotta8
- Camilla Frieri8
- Simona Sica12
- Patrizia Chiusolo12
- Christian Chabannon4
- Sabine Furst4
-
Armando Santoro13
- Andrea Bacigalupo12
- Benedetto Bruno9
- Didier Blaise14
- Domenico Mavilio15
-
Stefania Bramanti1
- Raynier Devillier4
- Emanuele Angelucci2
- Luca Castagna1
- 1. IRCCS Humanitas Research Hospital, via Manzoni 56, 20072 Rozzano (Mi) - Italy
- 2. Hematology and Bone Marrow Transplant Unit, Ospedale Policlinico San Martino, Genoa, Italy
- 3. Unit of Clinical Epidemiology, Città della Salute e della Scienza di Torino, Torino, Italy
- 4. Department of Hematology, Transplantation Program, Institut Paoli-Calmettes, Marseille, France
- 5. Hematology and Transplant Center Unit, Udine University Hospital, DAME, University of Udine, 33100, Udine, Italy
- 6. Department of Oncology and Hematology Bone Marrow Transplant Unit Fondazione Casa Sollievo della Sofferenza San Giovanni Rotondo, Torino, Ital
- 7. Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
- 8. Department of Clinical Medicine and Surgery, Bone Marrow Transplant Center, Federico II University of Naples, Naples, Italy
- 9. Department of Oncology/Hematology, A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy
- 10. Department of Oncology/Hematology, A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy AND Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
- 11. Department of Oncology and Hematology Bone Marrow Transplant Unit Fondazione Casa Sollievo della Sofferenza San Giovanni Rotondo, Torino, Italy
- 12. Istituto di Ematologia, Fondazione Policlinico Universitario A.Gemelli, Universita' Cattolica, Roma, Italy
- 13. IRCCS Humanitas Research Hospital, via Manzoni 56,20089 Rozzano (Mi) - Italy AND Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele – Milan, Italy
- 14. Department of Hematology, Transplantation Program, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France
- 15. IRCCS Humanitas Research Hospital, via Manzoni 56, 20072 Rozzano (Mi) - Italy AND Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy
Description
This record contains raw data related to article “Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide"
Abstract
Donor selection may contribute to improve clinical outcomes of T cell-replete haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy). Impact of second-degree related donor (SRD) was not fully elucidated in this platform. We retrospectively compared the outcome of patients receiving Haplo-SCT either from a SRD (n = 31) or a first-degree related donor (FRD, n = 957). Median time to neutrophil and platelet recovery did not differ between a SRD and a FRD transplant (p = 0.599 and 0.587). Cumulative incidence of grade II-IV acute graft-versus host disease (GVHD) and moderate-severe chronic GVHD was 13% and 19% after SRD vs 24% (p = 0.126) and 13% (p = 0.395) after FRD transplant. One-year cumulative incidence of non-relapse mortality (NRM) was 19% for SRD and 20% for FRD (p = 0.435) cohort. The 3-year probability of overall survival (OS) and progression-free survival (PFS) was 42% vs 55% (p = 0.273) and 49% vs 35% (p = 0.280) after SRD and FRD transplant, respectively. After propensity score adjustment or matched pair analysis, the outcome of patients receiving Haplo-SCT from a SRD or a FRD did not differ in terms of NRM, OS, PFS, acute and chronic GVHD. Our results suggest that a SRD is a viable option for Haplo-SCT with PT-Cy when a FRD is not available.
Files
Restricted
The record is publicly accessible, but files are restricted to users with access.
Request access
If you would like to request access to these files, please fill out the form below.
You need to satisfy these conditions in order for this request to be accepted:
This set of raw data is accessible under request because they include sensitive data.
Please write your request at biblioteca@humanitas.it
You are currently not logged in. Do you have an account? Log in here
Additional details
Related works
- Is supplement to
- Journal article: 36057732 (PMID)
- Journal article: 10.1038/s41409-022-01565-1 (DOI)